Arcutis Biotherapeutics, Inc. (ARQT)
28.26
+0.73
(+2.65%)
USD |
NASDAQ |
Nov 13, 16:00
28.26
0.00 (0.00%)
After-Hours: 19:59
Arcutis Biotherapeutics Gross Profit Margin (Quarterly) : 91.34% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 91.34% |
| June 30, 2026 | 91.58% |
| March 31, 2026 | 90.72% |
| December 31, 2025 | 90.97% |
| September 30, 2025 | 91.25% |
| June 30, 2025 | 90.81% |
| March 31, 2025 | 86.59% |
| December 31, 2024 | 90.32% |
| September 30, 2024 | 87.70% |
| Date | Value |
|---|---|
| June 30, 2024 | 88.77% |
| March 31, 2024 | 93.43% |
| December 31, 2023 | 81.93% |
| September 30, 2023 | 96.37% |
| June 30, 2023 | 79.54% |
| March 31, 2023 | 71.84% |
| December 31, 2022 | 75.45% |
| September 30, 2022 | 30.34% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| ADMA Biologics, Inc. | 70.77% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 14.93% |
| Return on Assets | 6.57% |
| Return on Invested Capital | 9.45% |
| Profit Margin (Quarterly) | 6.12% |
| Operating Margin (Quarterly) | 6.56% |
| Return on Net Operating Assets | 13.94% |